The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. Issue 30 (9th July 2015)

• Record Type: Journal Article
• Authors: Geldenhuys, Hennie; Mearns, Helen; Miles, David J.C.; Tameris, Michele; Hokey, David; Shi, Zhongkai; Bennett, Sean; Andersen, Peter; Kromann, Ingrid; Hoff, Søren T.; Hanekom, Willem A.; Mahomed, Hassan; Hatherill, Mark; Scriba, Thomas J.; van Rooyen, Michele; Bruce McClain, J.; Ryall, Robert; de Bruyn, Guy; the H4:IC31 Trial Study Group
• Is Part Of: Vaccine. Volume 33:Issue 30(2015)
• Page Start: 3592
• Page End: 3599
• Publication Date: 2015-07-09
• Subjects: Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.05.036
• Languages: English
• ISSNs: 0264-410X

Abstract

<abstract abstract-type="author" id="abs0005"> <title id="sect0005">Abstract</title> <sec> <title id="sect0010">Background</title> <p id="spar0005">New, more effective vaccines to prevent tuberculosis (TB) disease are needed urgently. H4:IC31 is an investigational vaccine that contains a fusion protein of the immunodominant antigens TB10.4 and Ag85B, formulated in IC31<sup>®</sup> adjuvant. We assessed the safety and immunogenicity of H4:IC31 in South African adults from a TB endemic setting.</p> </sec> <sec> <title id="sect0015">Methods</title> <p id="spar0010">In this double blind, placebo controlled, phase I trial, <italic>Mycobacterium tuberculosis</italic>-uninfected, HIV-uninfected, healthy adults with a history of childhood BCG vaccination were randomly allocated to two intramuscular vaccinations with 5, 15, 50 or 150 μg H4 formulated in 500 nmol IC31<sup>®</sup>, two months apart. Vaccinees were followed for six months to assess safety; immunogenicity was measured by ELISpot and intracellular cytokine staining assays.</p> </sec> <sec> <title id="sect0020">Results</title> <p id="spar0015">Thirty-two participants received H4:IC31 and 8 received placebo. Injection site adverse events were common but mild; mild fatigue was the most common systemic adverse event. Frequencies of adverse events did not differ between dosage groups. Detectable antigen-specific CD4 T cell responses were induced by all doses of H4:IC31, but doses below 50 μg induced the highest frequencies of CD4 T cells, comprised predominantly of IFN-γ<sup>+</sup>TNF-α<sup>+</sup>IL-2<sup>+</sup> or TNF-α<sup>+</sup>IL-2<sup>+</sup> cells. These memory responses persisted up to the end of follow up, on study day 182.</p> </sec> <sec> <title id="sect0025">Conclusions</title> <p id="spar0020">H4:IC31 demonstrated an acceptable safety profile and was immunogenic in South African adults. In this trial, the 15 μg dose appeared to induce the most optimal immune response.</p> </sec> </abstract>